Results from phase I dose escalation of IMC-F106C, the first PRAME X CD3 ImmTAC bispecific protein in solid tumors
Authors
Hamid, O.Sato, T.
Davar, D.
Callahan, M. K.
Thistlethwaite, Fiona C
Aljumaily, R.
Johnson, M. L.
Arkenau, H. T.
Dumbrava, E. E. I.
Izar, B.
Chen, H. A.
Marshall, S.
Yuan, Y.
Deo, M.
Stanhope, S.
Collins, L.
Mundy, R.
Abdullah, S. E.
Lopez, J. S.
Affiliation
The Angeles Clinic And Research Institute, A Cedars Sinai Affiliate, 90025Issue Date
2022
Metadata
Show full item recordCitation
Hamid O, Sato T, Davar D, Callahan MK, Thistlethwaite F, Aljumaily R, et al. Results from phase I dose escalation of IMC-F106C, the first PRAME X CD3 ImmTAC bispecific protein in solid tumors. Annals of Oncology. 2022 Sep;33(7):S875-S. PubMed PMID: WOS:000866211600716.Journal
Annals of OncologyDOI
10.1016/annonc/annonc1058Additional Links
https://dx.doi.org/10.1016/annonc/annonc1058Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/annonc/annonc1058